![]()
|
|
||||||||
J. Biol. Chem., Vol. 275, Issue 37, 29091-29099, September 15, 2000
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
,
From the
Department of Molecular Biosciences and the
¶ Department of Pathology, Microbiology, and Immunology, School of
Veterinary Medicine, University of California,
Davis, California 95616 and the § Department of
Chemistry and Intercollege Mass Spectrometry Center, 152 Davey
Laboratory, The Pennsylvania State University,
University Park, Pennyslvania 16802
Received for publication, February 18, 2000, and in revised form, June 1, 2000
| |
ABSTRACT |
|---|
|
|
|---|
A single administration of monocrotaline to rats
results in pathologic alterations in the lung and heart similar to
human pulmonary hypertension. In order to produce these lesions,
monocrotaline is oxidized to monocrotaline pyrrole in the liver
followed by hematogenous transport to the lung where it injures
pulmonary endothelium. In this study, we determined specific
endothelial targets for 14C-monocrotaline pyrrole
using two-dimensional gel electrophoresis and autoradiographic
detection of protein metabolite adducts. Selective labeling of specific
proteins was observed. Labeled proteins were digested with trypsin, and
the resulting peptides were analyzed using matrix-assisted laser
desorption ionization mass spectrometry. The results were searched
against sequence data bases to identify the adducted proteins. Five
abundant adducted proteins were identified as galectin-1,
protein-disulfide isomerase, probable protein-disulfide isomerase
(ER60), The pyrrolizidine alkaloid monocrotaline
(MCT)1 is a phytotoxin used
experimentally to cause a pulmonary vascular syndrome in rats
characterized by proliferative pulmonary vasculitis, pulmonary hypertension (PH), and cor pulmonale (1-3). Although MCT intoxication is used as a model for studying human PH, the initiating mechanism(s) by which this agent produces PH have remained elusive. To produce pulmonary insult, MCT must first be activated by the liver to the
putative electrophile monocrotaline pyrrole (MCTP) (4, 5) which has
characteristics of a bifunctional cross-linking agent and has a
half-life of ~3 s in aqueous environments near neutral pH (6).
Stabilization of MCTP by red blood cells facilitates subsequent
transport to the lung (7). The evidence for the involvement of the
pulmonary endothelium as the target for MCT intoxication is supported
by the circulatory proximity of the liver to the lung endothelium,
evidence of increased thymidine uptake and decreased
5-hydroxytryptamine clearance by endothelial cells, and
extravasculature leakage of large macromolecules (2, 8, 9). Human
primary PH is hypothesized to be an inheritable dysfunction of the
pulmonary vascular endothelial cells (10). In primary PH, disturbance
of the endothelial cell surface is suspected to be the initiating
factor in the formation of platelet aggregates (11) and cause
the presence of in situ thrombosis (12, 13). In
vitro experiments with bovine pulmonary artery endothelial cells
have shown that MCTP can cause a moderate decrease in their ability to
act as a permeability barrier (14), cell proliferation is inhibited
(15), prolonged cell cycle arrest in G2-M occurs (16, 17), and cells
unable to correct or compensate for electrophilic insult often undergo
apoptosis (18). Apoptosis has recently been shown to occur in rat
pulmonary artery endothelial cells following the in vivo
administration of MCT (19).
Previous work has supported the involvement of endothelial cells as the
target for MCT-induced pulmonary hypertension; however, the
mechanism(s) by which these cells lose their ability to function correctly is unknown. With respect to pyrrole adduct formation this has
been restricted to the measurement of covalent binding to endothelial
cell DNA (16, 20). MCTP has been shown to react in a facile manner with
the thiol groups of cysteine and glutathione (21-25). A carbonium ion
can be generated at both the C7 and the C9 positions on the pyrrole
ring with the pyrrole structure being stabilized by resonance
structures that share a charge with the bridge head nitrogen (26). This
delocalization of charge for MCTP confers soft electrophile
characteristics (27, 28) in line more with reactivity toward soft
nucleophile protein side chains than with nucleic acids, which are
harder nucleophiles. It has previously been shown that MCTP reacts with
thiol groups on proteins such as hemoglobin (22, 29, 30). Of the
limited number of proteins identified as specific targets for MCTP,
cytochrome P450 3A, which is responsible for the dehydrogenation of
MCT, has also been shown to form adducts with pyrroles (31).
In this study we have coupled the use of two-dimensional gel
electrophoresis and matrix-assisted laser desorption ionization (MALDI)
to identify five major MCTP target proteins in human lung endothelial
cells and discuss their potential relevance to the enigmatic
process of pulmonary hypertension.
Production of 14C-Monocrotaline
Pyrrole--
All reagents unless otherwise indicated were obtained
from Fisher. Crotalaria spectabilis was grown under a
confined atmosphere of 14CO2, and the
14C-monocrotaline (14C-MCT, purity
>98%) was extracted and purified as described before (32).
14C-MCT was converted to 14C-monocrotaline
pyrrole (14C-MCTP, 1.95 mCi/mmol) by the method of Mattocks
et al. (33) using tetrabromo-1,2-benzoquinone (Aldrich); the
product was recrystallized in hexane:diethyl ether. Using fast atom
bombardment mass spectrometry the conversion of MCT to MCTP was found
to be complete; daughter spectra contained ions characteristic of the
pyrrole (34). 14C-MCTP was stored in
N,N-dimethylformamide at Tissue Culture and Sample Preparation--
Normal human
pulmonary artery endothelial cells (passage 7-8) (Clonetics, San
Diego, CA), from a 34-year-old female were grown to 80-90% confluence
prior to treatment. Cells in 175-cm2 flasks (Falcon
polystyrene) were incubated at 37 °C, 5% CO2 with humidity in EGM-2 medium (Clonetics). The medium was replaced with
EGM-2 without 10% fetal bovine serum immediately before exposing cells
to 105 µM 14C-MCTP delivered in 12.9 µl of
N,N-dimethylformamide/25 ml of media. Cells were
removed from flasks using 39-cm cell scrapers (Sarstedt, Newton, NC).
After pelleting, the cells were washed three times with isotonic
phosphate-buffered saline (136.89 mM NaCl, 2.68 mM KCl, 10.14 mM
Na2HPO4, and 1.76 mM
KH2PO4, pH, 7.4). The supernatant was removed,
and the cells from five flasks were combined, lysed in a 9 M urea (ultra pure) solution containing 4% CHAPS
(99%), all obtained from Amersham Pharmacia Biotech plus 40 mM Tris and Two-dimensional Gel Electrophoresis and
Autoradiography--
Protein samples (60 µl, 400 µg of protein)
were diluted to 250 µl with 8 M urea, 2% CHAPS, 18 mM dithiothreitol, and IPG buffer pH 4-7 was added
directly to give a final concentration of 2%. Electrophoresis reagents
and hardware, including the Multiphor II platform and EPS 3500XL power
supply were purchased from Amersham Pharmacia Biotech. A trace of
bromphenol blue was added, and samples (250 µl) were placed in a
Immobiline DryStrip reswelling tray. Immobiline DryStrips (IPG) (13 cm,
pH 4-7) were placed gel side down in sample, and a layer of mineral
oil was added. Samples were allowed to equilibrate with the strips
overnight. Isoelectric focusing was performed on a MultiPhor II
platform at 15 °C, and strips were covered with mineral oil with the
following voltage program: 360 V, 3 h; 1400 V, 0.5 h; 2600 V,
29 h, maximum current 1 mA. IPG strips were stored under
N2 in acid-washed glass tubes at Tryptic Digestion for Peptide Mass Fingerprinting--
Sections
of membrane containing protein were added to microreaction vessels (0.3 ml) fitted with PTFE-lined caps (Supelco, Bellefonte, PA) and
washed with 300 µl of distilled water. Protein spots were then
covered with 7 µl of 50 mM ammonium bicarbonate containing 1% n-octyl- Mass Spectrometry--
Molecular masses of tryptic peptides were
determined using a Voyager-DE STR MALDI-TOF mass spectrometer
(Perseptive Biosystems, Framingham, MA), using a nitrogen laser (337 nm) for ionization. A 10 mg/ml solution of recrystallized
Western Analysis of PDI and Galectin-1--
An additional blot
and the corresponding autoradiographic analysis were performed for
antibody detection of PDI and galectin-1. PVDF membranes were stained
with sulforhodamine B, and the proteins were matched with
autoradiographic spots. The location of spots previously identified by
peptide mass fingerprinting to correspond to galectin-1 and PDI were
marked by recording their horizontal and vertical position prior to
destaining with 100% methanol and a final rinse with 70%
acetonitrile. Blots were sectioned in half, and one portion developed
for galectin-1 and the other PDI. Membranes were first blocked with 3%
nonfat milk (Bio-Rad) in 150 mM NaCl, 50 mM
Tris buffer (TBS), pH 7.4, for 30 min at ambient conditions. This was
followed by an overnight incubation with primary antibodies at 4 °C.
The primary antibodies were polyclonal rabbit-raised against rat
galectin-1 (generously provided by D. N. W. Cooper from
UCSF), used at a concentration of 100 µl of serum/20 ml of 3%
milk TBS and a mouse monoclonal raised against rat protein-disulfide isomerase synthetic peptide (amino acids 499-509) with a working concentration of 2 µg/ml. The latter was obtained from StressGen Biotechnologies Corp., Victoria, British Columbia, Canada and is known
to cross-react with human PDI and calreticulin. After the overnight
incubation the blots were washed four times with TBS, and the secondary
antibody either goat anti-rabbit or anti-mouse conjugated with alkaline
phosphatase (Bio-Rad) was applied at a 1/2000 dilution in 3% milk TBS.
Incubations were carried out for 1.5 h at ambient conditions, and
the blots were subsequently washed with 0.05% Tween-20 in TBS (two
times) followed by four washes with TBS. Blots were developed for 10 min with alkaline phosphatase conjugation substrate kit (Bio-Rad).
Two-dimensional Gel Electrophoresis, Autoradiography, and Peptide
Mass Fingerprinting--
Results recorded in Fig.
1 show that a selective number of
proteins form covalent adducts with MCTP. This pattern was consistent from separation to separation, with six separate autoradiographic profiles showing the identical pattern of labeling. Of the 13 labeled
spots, seven were chosen for analysis based on the amount of
radioactivity associated with them and the intensity of the corresponding sulforhodamine B stain. The latter was used to pick protein spots that were in sufficient quantity and purity to have a
reasonable chance of producing an unambiguous match with protein data
bases. Of these seven spots, five were identified (Table I) as probable protein-disulfide
isomerase precursor ER-60 (EC 5.3.4.1, Swiss-Prot P30101),
protein-disulfide isomerase precursor (PDI, EC 5.3.4.1, Swiss-Prot
P07237), Antibody Recognition of Galectin-1 and PDI--
Because these are
two of the more interesting proteins found to be adducted by pyrroles,
we determined if for future experiments they could be more simply
identified through the use of antibody techniques. Results are recorded
in Fig. 4. The commercially available antibody to PDI was found to react with the protein previously identified using MALDI. The antibody also reacted with another protein,
which had an estimated pI and molecular weight that corresponded to
calreticulin, a protein specified by the manufacture to also react with
this antibody. This spot has been tentatively identified as such in
Fig. 4. The polyclonal rabbit antibody raised against rat lung
galectin-1 was found to also cross-react with human endothelial cell
galectin-1 previously identified by MALDI. The antibody did not
cross-react with any other proteins contained within the section of the
membrane designated for testing.
Autoradiographic analysis showed that MCTP forms covalent adducts
with specific proteins. Of these, we identified the following abundant
endothelial proteins as targets for pyrrole adduct formation: galectin-1 (Swiss-Prot P09382), PDI precursor (EC 5.3.4.1, Swiss-Prot P07237), probable protein-disulfide isomerase ER-60 (EC
5.3.4.1, Swiss-Prot P30101), Such selectivity has been observed for a number of electrophiles, one
of the best studied being the arylation of proteins by
acetaminophen-derived electrophile,
N-acetyl-p-benzoquinone imine (43). The proteins
identified in this study serve functions that are potentially important
in the maintenance of the endothelial cell barrier. Alterations in
these functions could be a mechanistic link between MCTP treatment and
the progression of vascular remodeling evident in the lung. However
this statement is tempered by the fact that for most compounds
attempts have failed to definitely link the event of covalent
adduct formation with cellular proteins to a toxic event observed in a
particular organ. Even for well studied compounds such as acetaminophen
this link is casual in that covalent binding is merely seen to parallel
the degree of hepatotoxicity (44).
Additional peaks that could be identified as adducted tryptic peptides
were not observed in the MALDI mass spectra. Recoveries of pyrrole
adducts were expected to be low owing to the lability of the pyrrole
adducts during work up in 50% formic acid solutions or because of
incomplete digestion of protein-containing intramolecular pyrrole
cross-links. We have previously
shown2 that
pyrrole-glutathione conjugates and pyrrole adduct peptides of
glutathione transferases are not stable to separations on silica-based reverse phase HPLC supports using trifluoroacetic acid in the mobile phase.
Previous examination of adducts formed from the reaction of MCTP with
synthetic peptides have revealed that the amino acids cysteine,
tryptophan, and histidine are the most likely targets for pyrrole
adduct formation (21, 30). Because these groups are present in many
proteins, accessibility of side chain nucleophiles and local
microenvironments that enhance side chain nucleophilicity are expected
to form the basis of selectivity in adduct formation. Galectin-1
contains six cysteine residues (4.5% of total amino acids), all of
which are in the reduced state (45). Hydropathicity calculations have
indicated that at least 50% of these cysteines are potentially exposed
to the aqueous environment. Both PDI and ER60 have two thioredoxin
domains/protein molecule that are redox active (46) and would provide
reduced cysteines to bind with pyrroles. Another interesting facet of
both PDI and ER60 is the presence of an acidic group that is positioned
close to the cysteines involved in the catalytic center of these
proteins. Chivers and Raines (47) have proposed that aspartate or
glutamate participate in a general acid/base catalysis scheme at the
active site (Cys-Xaa-Xaa-Cys) involved in the thiol:disulfide
oxidoreduction carried out by Escherichia coli thioredoxin.
These authors pointed out that this feature is also present in human
PDI. Examination of ER60 also shows a similar sequence of amino acids
and the presence of glutamate. For example E. coli
thioredoxin (Swiss-Prot no. P00274) has the sequence
DFWAEWCGPCKM (residues 26-37), human
PDI precursor (Swiss-Prot no. P07237) is
EFYAPWCGHCKA, (residues 47-58), and
ER60 (Swiss-Prot # P30101) is
EFFAPWCGHCKR (residues 51-62). The
importance of the proximity of the glutamate residue to the thiol group
stems from the potential for the carboxylate to enhance thiol
reactivity via general base catalysis. Because the reactivity of MCTP
or dehydroretronecine toward protein nucleophiles involves first the
release of the alkaloid ester or hydroxyl groups (respectively)
producing a carbonium ion the presence of acidic groups could increase
the alkylating potential of pyrroles (48). Protons donated by glutamic
or aspartic acid drive this release under the general mechanism of acid
catalysis. Therefore, proton donors near cysteine would be expected to
increase their susceptibility to alkylation by pyrroles through an
SN1 mechanism. Based upon nucleic acid sequencing, PDI has
six cysteine residues in its mature form. The two cysteine residues
that are not in thioredoxin-like sites are reactive to iodoacetamide
(49) but only under denaturing conditions; this would leave only the
hyperreactive Cys-Xaa-Xaa-Cys motifs for MCTP to target. Both The potential biological relevance of these proteins in an emerging
model of MCTP-induced pulmonary hypertension will be discussed with an
emphasis being placed on exploring the known functions of these
proteins and the observed pulmonary physiological alterations, which
typify the disease.
Galectin-1 is a lectin or carbohydrate-binding protein, which in its
dimeric state possesses two galactoside binding sites (50). The dimeric
state can thus participate in both intramolecular and intermolecular
cross-linkings through the interaction of more than one sugar residue
(50). Intermolecular cross-linking capabilities have been used as an
assay for galectin-1 activity by exploiting its agglutination of
erythrocytes (45). The proposed biological functions of galectin-1
include adhesion in cell-cell and cell-extracellular matrix
interactions, concentration-dependent induction and
inhibition of cell proliferation, and the ability to induce apoptosis
(50). In rat lung, the The conversion of galectin-1 to a mitogen could explain some of the
observed pulmonary changes following the in vivo
administration of MCT. Feeding of C. spectabilis seeds to
rats results in a significant proliferative response in endothelial
cells, fibroblasts, and smooth muscle cells as measured by the uptake
of [3H]thymidine (8). Galectin-1 has also been shown to
form associations with extracellular matrix (ECM) proteins such as
laminin and fibronectin (50) and promote cell adhesion to the ECM. Its
interaction with ECM proteins has been implicated in the modulation of
the spread and migration of vascular smooth muscle cells (56).
Alteration in the ECM because of changes in galectin-1 may result in a
matrix unable to act as a sufficient anchor for endothelial cells
resulting in either loss of cells or the microvascular leakage that is
observed in the MCT model.
Galectin-1 has also been shown to effect the release of cytotoxin from
murine macrophage and human monocytes (57). One of the earliest
morphological changes in the pulmonary vasculature of MCT-exposed rats
is the accumulation of mononuclear inflammatory cells in the small
intraacinar vessels and this is associated with or precedes the
accumulation of edema fluid and inflammation (58).
Galectins have been implicated as participants in cell adhesion, cell
growth, immunomodulation, inflammation, embryogenesis, apoptosis,
pre-mRNA splicing, and metastasis. Although there are numerous
biochemical and molecular studies relative to galectins, their in
vivo role is basically unknown (59); however, the properties of
galectin-1 make it an attractive and never before considered participant in the pathology induced by MCT treatment.
PDI is located in the lumen of the endoplasmic reticulum at
concentrations approaching mM levels (49) and is
responsible for the insertion of disulfides into folding proteins as
well as correcting errors in disulfide formation (60). This process is
achieved by a mechanism of thiol/disulfide exchange (60). PDI has two
active sites each containing two cysteines separated by glycine and
histidine (61-63). PDI also has been shown to act as a chaperone that
binds to unfolded proteins and prevents their aggregation with other
proteins (64-67). It acts as a subunit for prolyl 4-hydroxylase as
well as microsomal triglyceride transfer protein (68). Because of the
numerous functions of PDI, alteration or loss of activity because of
alkylation or indirect perturbation in the redox environment by
pyrroles could rapidly endanger the homeostasis of the endothelial cell.
Peptide mapping of spot 4 indicated the presence of either the Studies with nonmuscle isoforms of cytoskeletal tropomyosin have shown
it to be important in the process of actin filament formation and
structure and in the defining of domains along the actin filament (72).
Tropomyosin can block the bundling of actin by villin (73), the
interaction of actin with filamin and The limited number of proteins that are bound by MCTP suggests
particular motifs that may be important for the binding of pyrroles and
thus narrows the search for other proteins that may be important to the
toxicology of MCT. Only a limited number of proteins possess
thioredoxin sites Cys-Xaa-Xaa-Cys (78). A few of these that were not
observed in this study, which are present in endothelial cells, are
fibronectin, thioredoxin, von Willebrand factor, and human RNA
polymerase. Fibronectin, which has PDI activity, is an important
component of the ECM and is necessary for endothelial integrity (79).
The von Willebrand factor is produced by endothelial cells and plays an
important role in platelet adherence to the interstitial matrix
following endothelial damage (80). One of the manifestations of primary
PH is the evidence of circulating platelet aggregations (11) and the
presence of in situ thrombosis in pulmonary lesions (12,
13). Human RNA polymerase contains three Cys-Xaa-Xaa-Cys regions with
one of these groups falling within a zinc finger. Perturbation in the
transcription of DNA into RNA would have obvious consequences. Some of
the 14C spots that remain to be identified could contain
proteins with the Cys-Xaa-Xaa-Cys motif or accessible reactive
cysteine(s). Additional proteins may be identified using different pH
gradients and blotting conditions. The technique employed in this paper probably missed many of the higher molecular weight proteins because of
the soaking technique employed and the gel composition of commercially available IGP strips (81, 82).
In the search for important molecular target(s) for MCTP, it should be
considered that only small quantities of electrophile (MCTP) are
essential to elicit pulmonary insult. Doses as low as 1 mg/kg,
administered intravenously in
N,N-dimethylformamide, were found to affect
pulmonary function in rats (83). With a half-life in aqueous solutions
of ~3 s (6), a significant portion of the dose would also be expected
to be lost before exacting an effect. Therefore proteins that are
abundant and structural in nature may not receive enough adduct to
significantly alter cellular function. However, as in the case of
actin, adducts to actin alone may not present problems to the cell but
actin cross-links to DNA may have more dire consequences (84). Proteins
that are found in low levels or function in enzymatic or signaling
processes are potentially better candidates. Alterations in a small
percentage of the PDI pool may be amplified if adducted PDI can still
participate in enzymatic processes resulting in the incorrect formation
of disulfides or fails to act as a proper chaperone causing the
aggregation of unfolded proteins. ER60 has previously been found to be
associated with the internal nuclear matrix and participates in the
anchorage of the DNA loops at the matrix (85). Such matrix DNA
interactions have been shown to be important in the control of gene
expression (86). Adducts that result in hypersensitivity reactions may also be important. PDI has been implicated in halothane hepatitis along
with other adducted proteins (87-89). Autoantibodies to PDI were
detected in rats exposed to D-galactosamine and
acetaminophen or carbon tetrachloride when the latter two were combined
with diethylmaleate (90). A similar mechanism may be relevant to MCTP toxicosis.
The proteins observed to form covalent adducts with MCTP and their
resulting partial or total loss of function could be important elements
in the puzzling model MCT-induced PH. Further exploration of these
proteins and their role in both chemically precipitated or natural
occurring PH warrant future investigation.
- or
-cytoplasmic actin, and cytoskeletal tropomyosin
(TM30-NM). With the exception of actin, the proteins identified in this
study have never been identified as potential targets for pyrroles, and
the majority of these proteins have either received no or minimal
attention as targets for other electrophilic compounds. The known
functions of these proteins are discussed in terms of their potential
for explaining the pulmonary toxicity of monocrotaline.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
![]()
MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
80 °C until just prior to use.
-toluenesulfonyl fluoride (Aldrich). The
latter was added just prior to use in 50 µl of absolute ethanol to
give a final concentration of 8 mM. Cells were disrupted
with 500 µl of the above, and the lysate was maintained at room
temperature for 1 h. The bicinchoninic acid method, as
described by the manufacturer (Pierce), was used to determine protein
concentrations. Following protein determination, dithiothreitol
(Amersham Pharmacia Biotech) was added to give a final concentration of
64.9 mM; lysate was retained at room temperature for an
additional 25 min followed by centrifugation (100,000 × g) for 1 h at 10 °C. Supernatants were stored under
N2 at
80 °C until needed.
80 °C prior to
separation on the second dimension. After removal from storage, strips
were allowed to just thaw before being first equilibrated in 30 ml of
50 mM Tris (pH 6.8) containing 30% v/v glycerol (ultra
pure), 2% SDS, 6 M urea, 16.2 mM
dithiothreitol, and a trace of bromphenol blue, followed by
equilibration in the same buffer system (30 ml) with the replacement of
dithiothreitol with 135 mM iodoacetamide (97%, Aldrich).
Each equilibration phase was of 10-min duration and performed by
placing IPG strips in a Petri dish with agitation generated by a rotary
shaker. IPG strips along with a 0.5 × 4-mm agarose cylinder
containing 0.5 µg of each molecular weight markers (14,000-66,000,
Sigma no. MW-SDS-70L) were sealed on top of a 145 × 140 × 1-mm Laemmli (35) separating gel (11% T, 2.7% C,
acrylamide (99.9%) and
bis-N,N'-methylenebisacrylamide were both
obtained from Bio-Rad using 0.5% agarose (SeaKem Gold, FMC, Rockland,
ME) dissolved in 125 mM Tris, pH 6.8, 0.1% SDS at
55 °C. Electrophoretic separations were performed at 4 °C, 10 mA/gel. Prior to protein transfers to Sequi-Blot PVDF membranes (0.2 µm, Bio-Rad), gels and membranes were equilibrated for 15 min in
transfer buffer (25 mM Tris, 192 mM glycine,
10% methanol). Overnight transfers were conducted using a Transphor
(TE 52) tank blotting unit (Hoefer Scientific Instruments, San
Francisco, CA), using the above buffer (4 °C), and the electrical
conditions were 30 V, 200 mA. Membranes were transferred to glass Pyrex
dishes and extensively rinsed with numerous changes of distilled water followed by drying under a stream of N2 and then a final
dehydration step in a vacuum desiccator under house vacuum. All
glassware used in this process and subsequent digestion protocols were
thoroughly cleaned employing sonication in dilute Alconox (Alconox,
Inc., New York, NY), and then 0.5 N HCl, distilled water rinses
following each procedure coupled with a terminal methanol (HPLC grade)
wash. The dried membrane was placed in an autoradiography cassette
FBXC and covered with a BioMax TranScreen-LE intensifying screen
containing BioMax MS film (Eastman Kodak). Cassettes were stored at
80 °C until the film was developed. After film development,
proteins were matched to autoradiographic film spots by staining the
membranes for 60 s with 0.005% w/v sulforhodamine B (laser grade,
Aldrich) in 30% v/v aqueous methanol containing 0.1% acetic acid with
gentle agitation, followed by a 30-s water rinse (36). Proteins
containing 14C-pyrrole adducts were excised for tryptic digestion.
-D-glucopyranoside
(Calbiochem) and 280 ng of sequencing grade-modified trypsin (Promega,
Madison, WI). Vials were sealed and placed in a secondary container,
which was subsequently immersed overnight in a water bath (28 °C).
Peptides were extracted from the PVDF matrix by adding 50 µl of a
50% ethanol (Aldrich, spectrophotometric grade): 50% formic acid
(purity 99%) to the digestion medium and sonicating vials in a Branson
ultrasonic cleaner (Shelton, CT) for 30 min. The extract was
concentrated to dryness in 100-µl glass Accuform Micro-Vials
(Kimble-Kontes, Vineland, NJ) using a Savant Speed Vac concentrator
(Laboratory Equipment Company, Hayward, CA); samples were stored at
80 °C until they were analyzed by MALDI.
-cyano-4-hydroxycinnamic acid (Aldrich) matrix was prepared in 50%
aqueous acetonitrile containing 0.3% trifluoroacetic acid. Peptide
digests were dissolved in 10 µl of 50% aqueous acetonitrile
containing 0.1% formic acid, and a 0.5-µl aliquot was mixed on the
sample target with 0.5 µl of matrix solution and allowed to dry under
ambient conditions. Multipoint mass axis calibration was performed
using external standards angiotensin I, ACTH(1-17), ACTH(18-39),
ACTH(7-38), and bovine insulin. Initial screening was performed in
linear mode, and more accurate monoisotopic peptide masses were
determined in reflector mode. To determine the identity of selected
spots, MS-Fit and in some cases MS-Tag were used to search data bases for peptide mass fingerprints and to match fragment ions observed in
post-source decay (PSD) spectra, respectively (37, 38). In addition to
the above data bases we have used the ExPASy Proteomics tool
ProtScale to accomplish hydropathicity calculations (39). These
calculations were used to determine the potential accessibility of
cysteine residues to MCTP.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
- or
-cytoplasmic actin (Swiss-Prot P02570 and P02571,
respectively), cytoskeletal tropomyosin (TM30-NM, Swiss-Prot P12324),
and galectin-1 (Swiss-Prot P09382). As recorded in Table I, both the
apparent molecular weights and estimated pIs from the two-dimensional
separations were in close agreement to data base values with the actual
tryptic peptide masses showing excellent coverage and agreement with
the expected theoretical values. Typical MALDI mass spectra for tryptic
digests of galectin-1 (linear mode) and PDI (reflector mode) are shown
in Figs. 2 and
3, respectively. PSD spectra were
generated to confirm assignments of tryptic fragments from each of
these two proteins. The PSD ions described here follow the nomenclature
of Biemann (40); fragmentation designation is followed in parenthesis
by the m/z value. For galectin-1 the peptide sequence
DSNNLCLHFNPR was chosen. The PSD ions showed the expected amino acid
immonium ions and numerous other expected fragments. Some of the more
prominent ions were the C-terminal ions y2 (272),
y2-NH3 (255), and y11 (1372);
N-terminal ions b4 (431), b6-H2O
(686), and c5 (561); and internal fragment ions NLCL (b
ion, 501) and CLHFN (b ion, 672). For PDI the peptide ILFIFIDSDHTDNQR
was subjected to PSD. Fragmentation for this peptide was not as
informative as that observed for the galectin-1 peptide because of the
complexity of the PSD spectrum, but the immonium ions for histidine,
isoleucine/leucine, and phenylalanine were present. Some of the more
prominent ions included m/z 1790, which represented the
MH+-45 (loss of the threonine side chain), y3
(417), NQ-NH3 (b ion, 226), FIFIDSDHT-H2O (b
ion, 1059), LFIFIDSDHT (b ion, 1190), and FIFIDSDHTD (a ion, 1164).
Spots three and five produced no meaningful matches considering
apparent molecular weight, estimated pI, or the peptide mass
fingerprint. There are also a number of discrete radiolabeled spots
that travel with the dye front. Because the number of known metabolites
and break down products of MCTP (24, 41, 42) cannot account for this
heavily labeled area, we suspect that these are proteolysis products
derived from adducted proteins.

View larger version (104K):
[in a new window]
Fig. 1.
A, two-dimensional protein gel
transferred to a PVDF membrane and subsequently stained with
sulforhodamine B. Proteins were derived from human pulmonary
endothelial cells previously exposed to 105 µM
14C-MCTP for 24 h. The numbers on the figure
correspond to radiolabeled regions excised for analysis by MALDI;
excised portions take on a squared appearance. The following numbers
correspond with the following proteins: 1, PDI;
2, ER60; 4,
- or
-cytoplasmic actin;
6, cytoskeletal tropomyosin; 7, galectin-1.
Library searches performed for the peptide mass fingerprints of spots 3 and 5 resulted in the absence of definitive matches. B
represents the corresponding autoradiograph of the membrane done prior
to the staining with sulforhodamine B and the subsequent excising of
spots for tryptic digestion and MALDI analysis. Note that images have
been inverted (white spots on a black background)
to enhance spot visualization.
Summary of MALDI masses obtained from tryptic digests of pyrrole
adducted proteins

View larger version (14K):
[in a new window]
Fig. 2.
MALDI spectrum (linear mode) of peptides
derived from the digestion of galectin-1 with trypsin. Numbers
positioned above ions represent the peptide sequence in the parent
protein. Ion masses corresponding to the tryptic fragments are listed
in Table I, except for span 29-36 (m/z 878) and the peptide
generated by a single missed cleavage by trypsin 74-111
(m/z 4334).

View larger version (22K):
[in a new window]
Fig. 3.
MALDI spectrum (reflector mode) of peptides
derived from the digestion of PDI with trypsin. Numbers positioned
above ions represent the peptide sequence in the parent protein. Ion
masses corresponding to the respective trypsin-generated peptides are
listed in Table I.

View larger version (129K):
[in a new window]
Fig. 4.
Two-dimensional gel of human endothelial
proteins transferred to PVDF membrane and subsequently reacted with the
primary antibodies to PDI and galectin-1. Regions located by the
use of a secondary antibody coupled to alkaline phosphatase. Prior to
localizing proteins through antibody detection, the blot was stained
with sulforhodamine B, spots containing 14C (determined
autoradiographically) and previously known to be galectin-1 and PDI by
MALDI peptide mass fingerprinting were marked (still visible) for both
their horizontal and vertical positions on the edges of the
membrane. The majority of sulforhodamine dye was removed prior to
antibody analysis by washing with methanol followed by 70%
acetonitrile. In the higher mass region of the blot containing PDI, an
additional spot is visible that has been tentatively identified
as calreticulin according to its apparent molecular weight, pI, and the
manufacture's designation of cross-reactivity.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
- or
-cytoplasmic actin (Swiss-Prot
P02570 and P02571, respectively), and cytoskeletal tropomyosin
(TM30-NM, Swiss-Prot P12324). Gel images in Fig. 1, A and
B, confirm this selectivity; numerous abundant proteins, in
and around the 66-kDa zone, are devoid or show nondiscrete traces of
associated radiolabel. This is readily observable in the abundant
protein just above spot 3. The lower left quadrant, a portion of the
blot containing proteins closer to an overall neutral pI, contains
numerous protein spots; however, they are not associated with
detectable levels of 14C. Other prominent examples of
selective adduct formation can be seen in the area of spot 6. This area
contains many sulforhodamine B-stained spots, yet only spot 6 shows
distinct and reproducible evidence of radiolabel incorporation. Among
the seven spots that we selected for identification, it is also
apparent that the degree of labeling does not correspond with the
amount of protein present. Gels stained with silver (not shown) or
blots developed with sulforhodamine B show that spot 5 is an abundant
protein, which is qualitatively equal in content to spots 1-4, 6, and
7. However, the degree of label associated with spot 5 appears to be
less when compared with these spots. Of the protein spots that
consistently contain 14C, the two unmarked spots (not
identified) near spot 7 also show intense radiolabeling and are not as
abundant as the proteins we have identified or attempted to
characterize. The degree of selectivity observed is not surprising
considering earlier work. Dehydroretronecine, a pyrrole formed from the
reaction of water with MCTP, could alkylate, in decreasing order of
reactivity, cysteine, tryptophan, and histidine. Adduct formation with
glutathione was more pronounced than with cysteine alone, indicating
that the environment of a thiol group can increase its reactivity to pyrrole (21). Adduct formation would thus be more favorable for
proteins containing a higher percentage of accessible cysteine residues
and a microenvironment that aids in thiol activation.
-actin
cytoplasmic 1 and cytoskeletal tropomyosin contain 1.6% cysteine, and
both also have acidic pIs, 5.29 and 4.75, respectively. Hydropathicity
calculations indicate that the cysteine residues of cytoskeletal
tropomyosin at positions 154, 226, and 233 are more negative than the
-actin cytoplasmic 1 residues at 257 and 272, which are suspected to
be in contact with the aqueous environment. From the autoradiograph it
also appears that tropomyosin is more extensively labeled, which would correlate with its more accessible thiol groups.
-galactoside-binding proteins are expressed in smooth muscle cells, type I alveolar epithelial cells, and are
concentrated extracellularly in elastic fibers of the pulmonary parenchyma and blood vessels (51, 52). Human aortic and umbilical vein
endothelial cells have also been shown to express galectin-1 in
vitro (53). In human aortic endothelial cells, the bulk of galectin is located within the interior of the cell with ~5% on the
surface. Stimulation of human aortic endothelial cells with minimally
oxidized low density lipoprotein resulted in a 47-79% increase in
galectin on the cellular surface (53). Similar findings were reported
for human umbilical vein endothelial cells. Both smooth muscle cells
and pulmonary artery endothelial cells have been observed to undergo
cellular proliferation when exposed to various lectins including
galectin (54). It has been suggested that galectin-1 could play a
significant role in stimulating smooth muscle growth in developing
alveolar wall vessels and the development of pulmonary capillaries
(54). Mitogenic versus sugar binding activity may be related
to the state of galectin sulfhydryl groups, because formation of two
intramolecular disulfide bonds caused the protein to act as a mitogen
but lacks sugar binding properties (55). The protein may exist in two
different states; as a monomer it has transforming growth factor
qualities, and as a dimer it acts as a lectin (55). MCTP binding could
either result in intramolecular or intermolecular cross-linking of
sulfhydryls with functional consequences for the sugar binding or
growth factor activities.
- or
-form of cytoskeletal actin but could not distinguish between the
two. Previously we have shown, using SDS-polyacrylamide gel
electrophoresis, Western blotting, and antibodies, that
-actin was a
potential target for pyrrole adduct formation (69). Actin is important
in the maintenance of the endothelial permeability barrier. Its
contractile interactions with myosin regulates the endothelial
permeability barrier and serves as an effector for inflammatory and
procoagulant-induced vascular leak. At cell-cell adherens junctions,
actin is linked to the plasma membrane through interactions with
-actinin, which associates with vinculin; vinculin is linked to
catenins and plakoglobin, which both interact with membrane-associated
cadherins. Cadherins in turn associate with cadherins from other cells
through their extracellular domains. In the subendothelial matrix,
fibronectin or vitronectin are bound to integrins, which bridge the
plasma membrane and in turn bind through talin to vinculin, which is
linked to
-actinin thus to actin filaments (70, 71). Alterations in
actin or other proteins involved in the normal functioning of the
endothelial barrier could result in extravascular leakage of plasma
proteins and fibrin, which could stimulate vascular wall remodeling.
-actinin (74, 75), and
inhibits fragmentation by gelsolin (76). In budding yeast, the loss of
the single copy gene for tropomyosin results in the disappearance of
cytoplasmic actin cables and reduced cell growth (77). These functions
make tropomyosin essential for normal cell division, locomotion, and
shape changes (72). This protein, like the actin it influences, could
be essential for preservation of the osmotic barrier provided by
functional endothelial cells and, along with DNA adducts, could
potentially explain some of the observed perturbations observed in the
cell cycle following MCTP treatment. Using methodologies similar to those employed in this study, acetaminophen has recently been shown to
form adducts with the hepatic derived cytoskeletal tropomyosin (37).
| |
FOOTNOTES |
|---|
* This work was supported by National Institutes of Health Grant HL48411 (to H. J. S.). The mass spectrometer was purchased in part with Grant RR11318 from the National Institutes of Health.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
To whom correspondence should be addressed: Dept. of Molecular
Biosciences, School of Veterinary Medicine, University of California, Davis, One Shields Ave., Davis, CA 95616. Tel.: 530-752-6173; Fax:
530-752-4698; E-mail: HJSegall@ucdavis.edu.
Published, JBC Papers in Press, June 29, 2000, DOI 10.1074/jbc.M001372200
2 M. W. Lamé, A. D. Jones, D. W. Wilson, S. K. Dunston, and H. J. Segall, unpublished results.
| |
ABBREVIATIONS |
|---|
The abbreviations used are: MCT, monocrotaline; PH, pulmonary hypertension; MCTP, monocrotaline pyrrole; MALDI, matrix-assisted laser desorption ionization; CHAPS, 3-[(3-cholamidopropyl)-dimethylammonio]-1-propane sulfonate; PVDF, polyvinylidene difluoride; HPLC, high pressure liquid chromatography; ACTH, adrenocorticotropic hormone; PSD, post-source decay; TBS, Tris-buffered saline; PDI, protein-disulfide isomerase; ECM, extracellular matrix.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Kay, J. M., and Heath, D. (1969) Crotalaria Spectabilis, the Pulmonary Hypertension Plant , pp. 1-146, C. C. Thomas, Springfield, IL |
| 2. | Wilson, D. W., Segall, H. J., Pan, L. C., Lamé, M. W., Estep, J. E., and Morin, D. (1992) Crit. Rev. Toxicol. 22, 307-325 |
| 3. | Chesney, C. F., and Allen, J. R. (1973) Am. J. Pathol. 70, 489-492 |
| 4. | Mattocks, A. R. (1968) Nature 217, 723-728 |
| 5. | Segall, H. J., Wilson, D. W., Lamé, M. W., Morin, D., and Winter, C. K. (1991) in Handbook of Natural Toxins, Toxicology of Plant and Fungal Compounds (Keeler, R. F. , and Tu, A. T., eds), Vol. 6 , pp. 3-26, Marcel Dekker, New York |
| 6. | Mattocks, A. R., and Jukes, R. (1990) Chem. Biol. Interact. 76, 19-30 |
| 7. | Pan, L. C., Lamé, M. W., Morin, D., Wilson, D. W., and Segall, H. J. (1991) Toxicol. Appl. Pharmacol. 110, 336-346 |
| 8. | Meyrick, B. O., and Reid, L. M. (1982) Am. J. Pathol. 106, 84-94 |
| 9. | Hoorn, C. M., and Roth, R. A. (1992) Am. J. Physiol. 262, L740-L747 |
| 10. | Voelkel, N. F., and Tuder, R. M. (1995) Eur. Respir. J. 8, 2129-2138 |
| 11. | Lopes, A. A., Maeda, N. Y., Almeida, A., Jaeger, R., Ebaid, M., and Chamone, D. F. (1993) Angiology 44, 701-706 |
| 12. | Fuster, V., Steele, P. M., Edwards, W. D., Gersh, B. J., McGoon, M. D., and Frye, R. L. (1984) Circulation 70, 580-587 |
| 13. | Wagenvoort, C. A., and Mulder, P. G. (1993) Chest 103, 844-849 |
| 14. | Taylor, D. W., Wilson, D. W., Lamé, M. W., Dunston, S. D., Jones, A. D., and Segall, H. J. (1997) Toxicol. Appl. Pharmacol. 143, 196-204 |
| 15. | Hoorn, C. M., Wagner, J. G., and Roth, R. A. (1993) Toxicol. Appl. Pharmacol. 120, 281-287 |
| 16. | Thomas, H. C., Lamé, M. W., Wilson, D. W., and Segall, H. J. (1996) Toxicol. Appl. Pharmacol. 141, 319-329 |
| 17. | Thomas, H. C., Lamé, M. W., Morin, D., Wilson, D. W., and Segall, H. J. (1998) Am. J. Respir. Cell Mol. Biol. 19, 129-142 |
| 18. | Thomas, H. C., Lamé, M. W., Dunston, S. K., Segall, H. J., and Wilson, D. W. (1998) Toxicol. Appl. Pharmacol. 151, 236-244 |
| 19. | Jones, P. L., and Rabinovitch, M. (1996) Circ. Res. 79, 1131-1142 |
| 20. | Wagner, J. G., Petry, T. W., and Roth, R. A. (1993) Am. J. Physiol. 264, L517-L522 |
| 21. | Mattocks, A. R., and Bird, I. (1983) Toxicol. Lett. 16, 1-8 |
| 22. | Mattocks, A. R., and Jukes, R. (1990) Chem. Biol. Interact. 75, 225-239 |
| 23. | Reed, R. L., Miranda, C. L., Kedzierski, B., Henderson, M. C., and Buhler, D. R. (1992) Xenobiotica 22, 1321-1327 |
| 24. | Lamé, M. W., Jones, A. D., Morin, D., Segall, H. J., and Wilson, D. W. (1995) Drug Metab. Dispos. 23, 422-429 |
| 25. | Robertson, K. A., Seymour, J. L., Hsia, M.-T., and Allen, J. R. (1977) Cancer Res. 37, 3141-3144 |
| 26. | Huxtable, R. J. (1979) Gen. Pharmacol. 10, 159-167 |
| 27. | Pearson, R. G., and Songstad, J. (1967) J. Am. Chem. Soc. 89, 1827-1836 |
| 28. | Coles, B. (1985) Drug Metab. Rev. 15, 1307-1334 |
| 29. | Seawright, A. A., Hrdlicka, J., Wright, J. D., Kerr, D. R., Mattocks, A. R., and Jukes, R. (1991) Vet. Hum. Toxicol. 33, 286-287 |
| 30. | Lamé, M. W., Jones, A. D., Morin, D., Wilson, D. W., and Segall, H. J. (1997) Chem. Res. Toxicol. 10, 694-701 |
| 31. | Reid, M. J., Lamé, M. W., Morin, D., Wilson, D. W., and Segall, H. J. (1998) J. Biochem. Mol. Toxicol. 12, 157-166 |
| 32. | Lamé, M. W., Morin, D., Wilson, D. W., and Segall, H. J. (1996) J. Label. Compd. Radiopharm. 38, 1053-1060 |
| 33. | Mattocks, A. R., Jukes, R., and Brown, J. (1989) Toxicon 27, 561-567 |
| 34. | Pan, L. C., Wilson, D. W., Lamé, M. W., Jones, A. D., and Segall, H. J. (1993) Toxicol. Appl. Pharmacol. 118, 87-97 |
| 35. | Laemmli, U. K. (1970) Nature 227, 680-685 |
| 36. | Pappin, D. J. C. (1997) in Methods in Molecular Biology, Protein Sequencing Protocols (Smith, B. J., ed), Vol. 64 , pp. 165-173, Humana Press, Totowa, NJ |
| 37. | Qiu, Y., Benet, L. Z., and Burlingame, A. L. (1998) J. Biol. Chem. 273, 17940-17953 |
| 38. | Clauser, K. R., Baker, P., and Burlingame, A. L. (1996) in Proceedings of the 44th ASMS Conference on Mass Spectrometry and Allied Topics, Portland, OR, May 12-16, p. 365 |
| 39. | Kyte, J., and Doolittle, R. F. (1982) J. Mol. Biol. 157, 105-132 |
| 40. | Biemann, K. (1990) Methods Enzymol. 193, 886-888 |
| 41. | Lamé, M. W., Jones, A. D., Morin, D., and Segall, H. J. (1991) Drug Metab. Dispos. 19, 516-524 |
| 42. | Lamé, M. W., Morin, D., Jones, A. D., Segall, H. J., and Wilson, D. W. (1990) Toxicol. Lett. 51, 321-329 |
| 43. | Cohen, S. D., and Khairallah, E. A. (1997) Drug Metab. Rev. 29, 59-77 |
| 44. | Boelsterli, U. A. (1993) Drug Metab. Rev. 25, 395-451 |
| 45. | Whitney, P. L., Powell, J. T., and Sanford, G. L. (1986) Biochem. J. 238, 683-689 |
| 46. | Freedman, R. B., Hirst, T. R., and Tuite, M. F. (1994) Trends Biochem. Sci. 19, 331-336 |
| 47. | Chivers, P. T., and Raines, R. T. (1997) Biochemistry 36, 15810-15816 |
| 48. | Culvenor, C. C. J., Edgar, J. A., Smith, L. W., and Tweeddale, H. J. (1970) Aust. J. Chem. 23, 1853-1867 |
| 49. | Lyles, M. M., and Gilbert, H. F. (1991) Biochemistry 30, 619-624 |
| 50. | Perillo, N. L., Marcus, M. E., and Baum, L. G. (1998) J. Mol. Med. 76, 402-412 |
| 51. | Cerra, R. F., Haywood-Reid, P. L., and Barondes, S. H. (1984) J. Cell Biol. 98, 1580-1589 |
| 52. | Leffler, H., and Barondes, S. H. (1986) J. Biol. Chem. 261, 10119-10126 |
| 53. | Baum, L. G., Seilhamer, J. J., Pang, M., Levine, W. B., Beynon, D., and Berliner, J. A. (1995) Glycoconj. J. 12, 63-68 |
| 54. | Sanford, G. L., and Harris-Hooker, S. (1990) FASEB J. 4, 2912-2918 |
| 55. | Yamaoka, K., Ingendoh, A., Tsubuki, S., Nagai, Y., and Sanai, Y. (1996) J. Biochem. 119, 878-886 |
| 56. | Moiseeva, E. P., Spring, E. L., Baron, J. H., and de Bono, D. P. (1999) J. Vasc. Res. 36, 47-58 |
| 57. | Kajikawa, T., Nakajima, Y., Hirabayashi, J., Kassai, K., and Yamazaki, M. (1986) Life Sci. 39, 1177-1181 |
| 58. | Wilson, D. W., Segall, H. J., Pan, L. C., and Dunston, S. K. (1989) Microvasc. Res. 38, 57-80 |
| 59. | Rabinovich, G. A. (1999) Cell Death Differ. 6, 711-721 |
| 60. | Gilbert, H. F. (1997) J. Biol. Chem. 272, 29399-29402 |
| 61. | Vuori, K., Myllylä, R., Pihlajaniemi, T., and Kivirikko, K. I. (1992) J. Biol. Chem. 267, 7211-7214 |
| 62. | Lyles, M. M., and Gilbert, H. F. (1994) J. Biol. Chem. 269, 30946-30952 |
| 63. | Walker, K. W., and Gilbert, H. F. (1997) J. Biol. Chem. 272, 8845-8848 |
| 64. | Cai, H., Wang, C.-C., and Tsou, C-L. (1994) J. Biol. Chem. 269, 24550-24552 |
| 65. | Quan, H., Fan, G., and Wang, C. (1995) J. Biol. Chem. 270, 17078-17080 |
| 66. | Song, J-L., and Wang, C-C. (1995) Eur. J. Biochem. 231, 312-316 |
| 67. | Yao, Y., Zhou, Y-C., and Wang, C.-C. (1997) EMBO J. 16, 651-658 |
| 68. | Wilson, R., Lees, J. F., and Bulleid, N. J. (1998) J. Biol. Chem. 273, 9637-9643 |
| 69. | Wilson, D. W., Lamé, M. W., Dunston, S. K., Taylor, D. W., and Segall, H. J. (1998) Toxicol. Appl. Pharmacol. 152, 138-144 |
| 70. | Lum, H., and Malik, A. B. (1994) Am. J. Physiol. 267, L223-L241 |
| 71. | Garcia, J. G. N., Verin, A. D., and Schaphorst, K. L. (1996) Semin. Thromb. Hemostasis 22, 309-315 |
| 72. | Fowler, V. M. (1990) J. Cell Biol. 111, 471-482 |
| 73. | Burgess, D. R., Broschat, K. O., and Hayden, J. M. (1987) J. Cell Biol. 104, 29-40 |
| 74. | Nomura, M., Yoshikawa, K., Tanaka, T., Sobue, K., and Maruyama, K. (1987) Eur. J. Biochem. 163, 467-471 |
| 75. | Zeece, M. G., Robson, R. M., and Bechtel, P. J. (1979) Biochim. Biophys. Acta 581, 365-370 |
| 76. | Fattoum, A., Hartwig, J. H., and Stossel, T. P. (1983) Biochemistry 22, 1187-1193 |
| 77. | Liu, H., and Bretscher, A. (1989) Cell 57, 233-242 |
| 78. | Boniface, J. J., and Reichert, L. E. (1990) Science 247, 61-64 |
| 79. | Langenbach, K. J., and Sottile, J. (1999) J. Biol. Chem. 274, 7032-7038 |
| 80. | Cotran, R. S., Kumar, V., and Robbins, S. L. (1994) in Robbins Pathologic Basis of Disease (Schoen, F. J., ed) , pp. 51-92, W. B. Saunders Co., Philadelphia, PA |
| 81. | Rabilloud, T., Valette, C., and Lawrence, J. J. (1994) Electrophoresis 15, 1552-1558 |
| 82. | Sanchez, J.-C., Rouge, V., Pisteur, M., Ravier, F., Tonella, L., Moosmayer, M., Wilkins, M. R., and Hochstrasser, D. F. (1997) Electrophoresis 18, 324-327 |
| 83. | Pan, L. C., Wilson, D. W., and Segall, H. J. (1993) Toxicology 79, 21-35 |
| 84. | Coulombe, R. A., Drew, G. L., and Stermitz, F. R. (1999) Toxicol. Appl. Pharmacol. 154, 198-202 |
| 85. | Ferraro, A., Altieri, F., Coppari, S., Eufemi, M., Chichiarelli, S., and Turano, C. (1999) J. Cell. Biochem. 72, 528-539 |
| 86. | van Driel, R., Humbel, B., and de Jong, L. (1991) J. Cell. Biochem. 47, 311-316 |
| 87. | Pohl, L. R., Kenna, J. G., Satoh, H., and Christ, D. (1989) Drug Metab. Rev. 20, 203-217 |
| 88. | Martin, J. L., Pumford, N. R., LaRosa, A. C., Martin, B. M., Gonzaga, H. M. S., Beaven, M. A., and Pohl, L. R. (1991) Biochem. Biophys. Res. Commun. 178, 679-685 |
| 89. | Pohl, L. R., Thomassen, D., Pumford, N. R., Butler, L. E., Satoh, H., Ferrans, V. J., Perrone, A., Martin, B. M., and Martin, J. L. (1990) in Biological Reactive Intermediates IV (Witmer, C. M., ed) , pp. 111-120, Plenum, New York |
| 90. | Nagayama, S., Yokoi, T., Kawaguchi, Y., and Kamataki, T. (1994) J. Toxicol. Sci. 19, 155-161 |
This article has been cited by other articles:
![]() |
M. F. Ramos, M. W. Lame, H. J. Segall, and D. W. Wilson Smad Signaling in the Rat Model of Monocrotaline Pulmonary Hypertension Toxicol Pathol, February 1, 2008; 36(2): 311 - 320. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. L. J. L. Thijssen, F. Poirier, L. G. Baum, and A. W. Griffioen Galectins in the tumor endothelium: opportunities for combined cancer therapy Blood, October 15, 2007; 110(8): 2819 - 2827. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. B. Sehgal, S. Mukhopadhyay, F. Xu, K. Patel, and M. Shah Dysfunction of Golgi tethers, SNAREs, and SNAPs in monocrotaline-induced pulmonary hypertension Am J Physiol Lung Cell Mol Physiol, June 1, 2007; 292(6): L1526 - L1542. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Sahara, M. Sata, T. Morita, K. Nakamura, Y. Hirata, and R. Nagai Diverse Contribution of Bone Marrow Derived Cells to Vascular Remodeling Associated With Pulmonary Arterial Hypertension and Arterial Neointimal Formation Circulation, January 30, 2007; 115(4): 509 - 517. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Mukhopadhyay and P. B. Sehgal Discordant regulatory changes in monocrotaline-induced megalocytosis of lung arterial endothelial and alveolar epithelial cells Am J Physiol Lung Cell Mol Physiol, June 1, 2006; 290(6): L1216 - L1226. [Abstract] [Full Text] |